Daisuke Shintani1, Hiroyuki Yoshida2, Akira Yabuno1, Keiichi Fujiwara1. 1. Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan. 2. Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan hiro_y@saitama-med.ac.jp.
Abstract
BACKGROUND/AIM: The aim of this study was to compare the tolerability and efficacy of bevacizumab monotherapy between older and younger patients with recurrent ovarian cancer. PATIENTS AND METHODS: We enrolled 32 patients with recurrent ovarian cancer who were treated with bevacizumab monotherapy and divided them into those who were 65 years and older (n=12) and those younger than 65 years (n=20). RESULTS: Except for grade ≥3 proteinuria, incidences of adverse events did not differ significantly between the groups. Although older patients exhibited more frequently cycle delay caused by non-hematological toxicities, this difference was not significant. There was no significant difference in tumor response and survival between the groups. CONCLUSION: Bevacizumab monotherapy was tolerable and effective for older patients with recurrent ovarian cancer compared with younger patients. Copyright
BACKGROUND/AIM: The aim of this study was to compare the tolerability and efficacy of bevacizumab monotherapy between older and younger patients with recurrent ovarian cancer. PATIENTS AND METHODS: We enrolled 32 patients with recurrent ovarian cancer who were treated with bevacizumab monotherapy and divided them into those who were 65 years and older (n=12) and those younger than 65 years (n=20). RESULTS: Except for grade ≥3 proteinuria, incidences of adverse events did not differ significantly between the groups. Although older patients exhibited more frequently cycle delay caused by non-hematological toxicities, this difference was not significant. There was no significant difference in tumor response and survival between the groups. CONCLUSION:Bevacizumab monotherapy was tolerable and effective for older patients with recurrent ovarian cancer compared with younger patients. Copyright
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: William P Tew; Hyman B Muss; Gretchen G Kimmick; Vivian E Von Gruenigen; Stuart M Lichtman Journal: J Clin Oncol Date: 2014-08-20 Impact factor: 44.544